You are here: Homepage Sectorfocus Life Sciences
Life Sciences
Meest recente
1 naar 10 van 406
-
Artikel
Ingediend: 07 March 2014
Revised draft rules for the Unified Patent Court have been issued.
-
Artikel
Laatst gecontroleerd: 12 February 2014 / Ingediend: 12 February 2014
A new judicial interpretation issued by the PRC Supreme People's Court strengthened the protections on consumers of food and pharmaceutical products.
-
Artikel
Ingediend: 07 February 2014
On 15 January 2014, Italy’s highest administrative court, the Council of State issued its decision in what is the final chapter in the Italian abuse of dominance saga involving Pfizer and generic pharmaceutical manufacturers.
-
Artikel
Ingediend: 04 February 2014
AG Opinion recommends that risk to the leniency programme should not justify categorically excluding liability of cartel members to pay compensation for umbrella pricing.
-
Artikel
Ingediend: 04 February 2014
Proposals for private actions for damages for competition law infringements have been laid before UK Parliament.
-
Artikel
Ingediend: 31 January 2014
The recent case of Telford Homes (Creekside) Limited v Ampurius Nu Homes Holdings Limited [2013] EWCA Civ 577 highlighted the risks for an innocent party in delaying a decision on whether or not to accept a repudiation of a contract.
-
Artikel
Ingediend: 30 January 2014
The new London Court of International Arbitration (LCIA) Rules.
-
Artikel
Laatst gecontroleerd: 27 January 2014 / Ingediend: 27 January 2014
A new regulation has been issued to allow wholly foreign investment in the medical service business in the Shanghai Free Trade Zone.
-
Artikel
Laatst gecontroleerd: 24 January 2014 / Ingediend: 24 January 2014
China is a popular place for R&D centers. Cooperation with fiscally funded institutions is proven to be efficient. A new draft regulation was issued on this.
-
Artikel
Ingediend: 22 January 2014
In this article we examine a recent case (in the electronics field) on the exercise of the discretion to refuse a final injunction and consider what implications this may have when the same question arises in the context of a dispute between originator pharmaceutical companies.
1 naar 10 van 406